PolyPeptide Group AG (LON:0AAJ)

Market Cap	523.12M
Revenue (ttm)	278.52M
Net Income (ttm)	-16.18M
Shares Out	n/a
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	244
Average Volume	2,301
Open	16.08
Previous Close	n/a
Day's Range	15.96 - 16.08
52-Week Range	14.19 - 25.84
Beta	1.02
RSI	52.34
Earnings Date	Aug 12, 2025

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 195...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1952
• Employees: 1,362
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0AAJ

Financial Performance

In 2024, PolyPeptide Group AG's revenue was 336.79 million, an increase of 5.13% compared to the previous year's 320.37 million. Losses were -19.56 million, -61.97% less than in 2023.

Financial numbers in EUR